These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25618150)

  • 1. Reducing risk and improving efficacy of clinical trials: the adaptive design.
    Dangi-Garimella S
    Am J Manag Care; 2014 Aug; 20(11 Spec No.):E8. PubMed ID: 25618150
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 4. Does study design explain the relationship between conflict of interest and positive outcome in clinical trials in psychiatry?
    Wu Y; Deboeck P; Joseph M; Hwang C; Perlis CS; Perlis RH
    J Clin Psychopharmacol; 2009 Dec; 29(6):609-11. PubMed ID: 19910733
    [No Abstract]   [Full Text] [Related]  

  • 5. A primer on the design, conduct, and interpretation of clinical trials.
    Appel LJ
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1360-7. PubMed ID: 17699370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bias control in clinical trials: masking or blinding.
    Galvez-Olortegui JK; Gonzales-Saldaña J; Garcia-Gomez I; Silva-Ocas I; Gutierrez-Arana J; Galvez-Olortegui T; Condor-Rojas YC
    Medwave; 2015 Dec; 15(11):e6349. PubMed ID: 26731671
    [No Abstract]   [Full Text] [Related]  

  • 8. Do randomised studies of traditional Asian therapies generate different results than non-randomised trials?
    Ernst E; Lee MS
    Int J Clin Pract; 2014 May; 68(5):655-7. PubMed ID: 24750528
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 10. [Don't throw out the observation studies with the bath-water. Assess their quality instead].
    Rosén M; Axelsson S; Lindblom J
    Lakartidningen; 2008 Nov 5-11; 105(45):3191-4. PubMed ID: 19062610
    [No Abstract]   [Full Text] [Related]  

  • 11. Sample size and threshold estimation for clinical trials with predictive biomarkers.
    Mackey HM; Bengtsson T
    Contemp Clin Trials; 2013 Nov; 36(2):664-72. PubMed ID: 24064355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACCE, pharmacogenomics, and stopping clinical trials: time to extend the CONSORT statement?
    Ozdemir V; Joly Y; Knoppers BM
    Am J Bioeth; 2011 Mar; 11(3):11-3. PubMed ID: 21400375
    [No Abstract]   [Full Text] [Related]  

  • 13. Controversy trails adaptive clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract]   [Full Text] [Related]  

  • 14. Can non-randomized trials be considered to be equivalent to randomized trials in forensic mental health?
    Leese M
    Crim Behav Ment Health; 2005; 15(2):121-2. PubMed ID: 16470506
    [No Abstract]   [Full Text] [Related]  

  • 15. Overhauling clinical trials.
    Scott CT; Baker M
    Nat Biotechnol; 2007 Mar; 25(3):287-92. PubMed ID: 17344876
    [No Abstract]   [Full Text] [Related]  

  • 16. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Q&A: Rajeshwari Sridhara, Robert Temple on trial design. Interviewed by Suzanne Rose.
    Sridhara R; Temple R
    Cancer Discov; 2013 Mar; 3(3):245. PubMed ID: 23475863
    [No Abstract]   [Full Text] [Related]  

  • 18. Time to adapt.
    Nature; 2010 Apr; 464(7293):1245-6. PubMed ID: 20428115
    [No Abstract]   [Full Text] [Related]  

  • 19. Study design: statistical and methodologic considerations.
    Rubenfeld GD
    Respir Care; 1995 Sep; 40(9):980-6. PubMed ID: 10152244
    [No Abstract]   [Full Text] [Related]  

  • 20. Time to rethink clinically important outcomes in platelet transfusion trials.
    Heddle NM; Arnold DM; Webert KE
    Transfusion; 2011 Feb; 51(2):430-4. PubMed ID: 21309780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.